

Benlysta® (belimumab)

Help Us Understand the Possible Effects of Benlysta® in Pregnancy

Many people need to take medication during pregnancy to appropriately manage a chronic health condition. In some cases, avoiding or stopping medication use during pregnancy may be more harmful than taking medication. Yet fewer than 10% of medications have enough information to determine their safety for use in pregnancy — this is where you come in!

MotherToBaby is currently enrolling pregnant women in a study examining the use of Benlysta® (belimumab) to treat systemic lupus erythematosus (or SLE, a type of lupus) or active lupus nephritis (lupus-related kidney inflammation) during pregnancy.

Are you currently pregnant? Did you take Benlysta® at any point in your current pregnancy? If you answered “yes” to both of these questions, then you have the opportunity to help us learn more about Benlysta®.

“There is a huge need to generate more data for all of the drugs that people who are pregnant need to take.”

— Christina Chambers, PhD, MPH, Lead Investigator, MotherToBaby Pregnancy Studies

Will you take the next step and become our partner? Make an impact on the health of future families today by joining our Benlysta® & Pregnancy Study!

JOIN A STUDY

REFER A PATIENT

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, September 23, 2022.

Benlysta® (belimumab)

This study is now closed to recruitment.

Thank you for your interest, but unfortunately we are no longer enrolling participants in this study. However, you may be eligible to participate in one of our other ongoing studies. Fill out your information using our [Join a Study](#) form, and a member of our team will contact you.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, September 23, 2022.

Benlysta® (belimumab)

This study is now closed to recruitment.

Thank you for your interest, but unfortunately we are no longer enrolling participants in this study. However, you may be eligible to participate in one of our other ongoing studies. Fill out your information using our [Join a Study](#) form, and a member of our team will contact you.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, September 23, 2022.

Benlysta® (belimumab)

This study is now closed to recruitment.

Thank you for your interest, but unfortunately we are no longer enrolling participants in this study. However, you may be eligible to participate in a study. Fill out your information using our [Join a Study](#) form, and a member of our team

will contact you.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, September 23, 2022.

Benlysta® (belimumab)

Help Us Better Understand the Possible Effects of Ilumya® in Pregnancy

Many people need to take medication during pregnancy to appropriately manage a chronic health condition. In some cases, avoiding or stopping medication use during pregnancy may be more harmful than taking medication. Yet fewer than 10% of medications have enough information to determine their safety for use in pregnancy — this is where you come in!

MotherToBaby is currently enrolling people who are pregnant in a study examining the use of Ilumya® (tildrakizumab-asmn) to treat psoriasis during pregnancy.

“There is a huge need to generate more info for all of the drugs that people who are pregnant need to take.”

--- Christina Chambers, PhD, MPH, Lead Investigator, MotherToBaby Pregnancy Studies

Are you currently pregnant? Did you take Ilumya® at any point in your current pregnancy? If you answered “yes” to both of these questions, then you have the opportunity to help us learn more about Ilumya® use in pregnancy.

Will you take the step and become our partner? Make an impact on the health of future families today by joining our Illumya® & Pregnancy Study!

JOIN A STUDY

REFER A PATIENT

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, September 23, 2022.